Diabetic Nephropathy Market

Best Price Guarantee	Length	Publisher	Published Date	SKU
from $4,850	120 Pages	Fortune Business Insights Pvt. Ltd.	October, 2024	FOB19224239

Best Price Guarantee
Price	from $4,850
Length	120 Pages
Publisher	Fortune Business Insights Pvt. Ltd.
Published Date	October, 2024
SKU	FOB19224239

Diabetic Nephropathy Market

Growth Factors of Diabetic Nephropathy Market

The global diabetic nephropathy market size was valued at USD 2.70 billion in 2023 and is projected to grow from USD 2.81 billion in 2024 to USD 3.99 billion by 2032, exhibiting a CAGR of 4.5% during the forecast period of 2024-2032.

This chronic illness disrupts the behind-schedule prognosis and treatment in the Diabetic Nephropathy Market because of limitations on healthcare admission and delayed trials. But, as other acts related to healthcare provision standardize, increased cases of diabetes and better awareness of kidney pains will, in turn, boost market expansion, thus restraining the diabetic nephropathy market growth.

The growth drivers for the Diabetic Nephropathy Market are the increasing prevalence of diabetes, increasing awareness of diabetic complications, and technological progress in the treatments. Growth in the prices of health and the advancement of fresh healing procedures contribute to the marketplace enlargement.

Remote monitoring and telemedicine are gradually becoming more and more crucial for controlling diabetic nephropathy. CGM gadgets show precise actual-time Blood Glucose degree knowledge to the sufferers and healthcare suppliers to make the suitable choice on insulin dosing and everyday way-of-life adjustments that would contribute to expanding the worldwide diabetic nephropathy market share. Telehealth platform Cornerstone also enables distant monitoring of patients with diabetic nephropathy and identifies potential complications and timely intervention. It can grow patient outcomes, reduce pressure on health systems, and improve regular, high-quality care.

Comprehensive Analysis of Diabetic Nephropathy Market

The Diabetic Nephropathy Market is segmented via drug magnificence and distribution channels. In terms of drug class, angiotensin receptor blockers maintain the most significant marketplace proportion due to their capacity to save nephropathy in diabetic sufferers. ACE inhibitors are also widely used, with medical research showing they sluggish the progression of kidney disorders. The SGLT2 inhibitors section is projected to develop quickly due to its blessings in decreasing renal fibrosis and related complications. Regarding distribution channels, clinic pharmacies dominate the market, driven by high hospitalization rates for persistent kidney sickness, even as drug shops and retail pharmacies preserve a significant percentage because they provide prescription and OTC drugs.

The North America region led the diabetic nephropathy market by benefitting a size of USD 1.19 billion in 2023 due to the rising prevalence of diabetes.

The leading players in the diabetic nephropathy market significantly shape its growth trajectory and establish industry standards. These key companies, including Janssen Pharmaceuticals, Inc. (U.S.), AstraZeneca (U.K.), Aurobindo Pharma Limited (India), Teva Pharmaceutical Industries Ltd. (Israel), Sanofi (France), Novartis AG (Switzerland), Sun Pharmaceutical Industries Ltd. (India), Bayer AG (Germany), and Par Pharmaceuticals (U.S.), contribute to a competitive landscape, driving innovation and advancing the market.

In November 2023, ProKidney Corp. Secured approval from the U.K. Medicines and Healthcare Products Regulatory Agency (MHRA) for proact 1 (REGEN-006) and obtained medical steerage from the European Medicines Agency (EMA) concerning phase 3 protocols for REACT in diabetic chronic kidney disease.

Segmentation Table

ATTRIBUTE DETAILS

Study Period 2019-2032

Base Year 2023

Estimated Year 2024

Forecast Period 2024-2032

Historical Period 2019-2022

Growth Rate CAGR of 4.5% from 2024-2032

Unit Value (USD Billion)

Segmentation By Drug Class

Angiotensin Converting Enzyme (ACE) Inhibitors
Angiotensin Receptor Blockers
Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors
Mineralocorticoid Receptor Antagonists
Others

By Distribution Channel

Hospital Pharmacies
Drug Stores & Retail Pharmacies
Others

By Geography

North America (By Drug Class, By Distribution Channel, and By Country)
U.S.
Canada
Europe (By Drug Class, By Distribution Channel, and By Country/Sub-region)
U.K.
Germany
France
Italy
Spain
Scandinavia
Rest of Europe
Asia Pacific (By Drug Class, By Distribution Channel, and By Country/Sub-region)
Japan
China
India
Australia
Southeast Asia
Rest of Asia Pacific
Rest of the World (By Drug Class, and By Distribution Channel)

Please Note: It will take 5-6 business days to complete the report upon order confirmation.

1. Introduction: 1.1. Market Scope; 1.2. Market Segmentation; 1.3. Market Methodology; 1.4. Definitions and Assumptions
2. Executive Summary
3. Market Dynamics: 3.1. Market Drivers; 3.2. Market Restraints; 3.3. Market Opportunities; 3.4. Market Trends
4. Key Insights: 4.1. Key Industry Developments – Merges, Acquisitions, and Partnerships; 4.2. New Product Launches, By Key Players; 4.3. Prevalence of Diabetic Nephropathy, By Key Countries; 4.4. Pipeline Analysis (Analysis by Stage, Route of Administration, Molecule Type, Sponsor, etc.); 4.5. Insights on Usage of SGLT2 Inhibitors in CKD Stage 3 Patients; 4.6. Drugs Delaying Dialysis Onset: Analysis of Ongoing Studies; 4.7. List of Research & Educational Institutes in R&D; 4.8. Impact of COVID 19 on the Global Diabetic Nephropathy Market
5. Global Diabetic Nephropathy Market Analysis, Insights and Forecast, 2019-2032: 5.1. Market Analysis, Insights and Forecast – By Drug Class; 5.1.1. Angiotensin Converting Enzyme (ACE) Inhibitors; 5.1.2. Angiotensin Receptor Blockers; 5.1.3. Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors; 5.1.4. Mineralocorticoid Receptor Antagonists; 5.1.5. Others; 5.2. Market Analysis, Insights and Forecast – By Distribution Channel; 5.2.1. Hospital Pharmacies; 5.2.2. Drug Stores & Retail Pharmacies; 5.2.3. Others; 5.3. Market Analysis, Insights and Forecast – By Region; 5.3.1. North America; 5.3.2. Europe; 5.3.3. Asia Pacific; 5.3.4. Rest of the World
6. North America Diabetic Nephropathy Market Analysis, Insights and Forecast, 2019-2032: 6.1. Market Analysis, Insights and Forecast – By Drug Class; 6.1.1. Angiotensin Converting Enzyme (ACE) Inhibitors; 6.1.2. Angiotensin Receptor Blockers; 6.1.3. Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors; 6.1.4. Mineralocorticoid Receptor Antagonists; 6.1.5. Others; 6.2. Market Analysis, Insights and Forecast – By Distribution Channel; 6.2.1. Hospital Pharmacies; 6.2.2. Drug Stores & Retail Pharmacies; 6.2.3. Others; 6.3. Market Analysis, Insights and Forecast – By Country; 6.3.1. U.S.; 6.3.2. Canada
7. Europe Diabetic Nephropathy Market Analysis, Insights and Forecast, 2019-2032: 7.1. Market Analysis, Insights and Forecast – By Drug Class; 7.1.1. Angiotensin Converting Enzyme (ACE) Inhibitors; 7.1.2. Angiotensin Receptor Blockers; 7.1.3. Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors; 7.1.4. Mineralocorticoid Receptor Antagonists; 7.1.5. Others; 7.2. Market Analysis, Insights and Forecast – By Distribution Channel; 7.2.1. Hospital Pharmacies; 7.2.2. Drug Stores & Retail Pharmacies; 7.2.3. Others; 7.3. Market Analysis, Insights and Forecast – By Country/Sub-region; 7.3.1. U.K.; 7.3.2. Germany; 7.3.3. France
8. 7.3.4.I taly: 8.1.; 8.1.1. Spain; 8.1.2. Scandinavia; 8.1.3. Rest of Europe
9. Asia Pacific Diabetic Nephropathy Market Analysis, Insights and Forecast, 2019-2032: 9.1. Market Analysis, Insights and Forecast – By Drug Class; 9.1.1. Angiotensin Converting Enzyme (ACE) Inhibitors; 9.1.2. Angiotensin Receptor Blockers; 9.1.3. Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors; 9.1.4. Mineralocorticoid Receptor Antagonists; 9.1.5. Others; 9.2. Market Analysis, Insights and Forecast – By Distribution Channel; 9.2.1. Hospital Pharmacies; 9.2.2. Drug Stores & Retail Pharmacies; 9.2.3. Others; 9.3. Market Analysis, Insights and Forecast – By Country/Sub-region; 9.3.1. Japan; 9.3.2. China; 9.3.3. India; 9.3.4. Australia; 9.3.5. Southeast Asia; 9.3.6. Rest of Asia Pacific
10. Rest of the World Diabetic Nephropathy Market Analysis, Insights and Forecast, 2019-2032: 10.1. Market Analysis, Insights and Forecast – By Drug Class; 10.1.1. Angiotensin Converting Enzyme (ACE) Inhibitors; 10.1.2. Angiotensin Receptor Blockers; 10.1.3. Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors; 10.1.4. Mineralocorticoid Receptor Antagonists; 10.1.5. Others; 10.2. Market Analysis, Insights and Forecast – By Distribution Channel; 10.2.1. Hospital Pharmacies; 10.2.2. Drug Stores & Retail Pharmacies; 10.2.3. Others
11. Comparative Analysis: 11.1. Global Market Share Analysis (2023); 11.2. Company Profiles; 11.2.1. Janssen Pharmaceuticals, Inc.; 11.2.1.1. Overview; 11.2.1.2. Products & Services; 11.2.1.3. SWOT Analysis; 11.2.1.4. Recent Developments; 11.2.1.5. Strategies; 11.2.1.6. Financials (Based on Availability); 11.2.2. AstraZeneca; 11.2.2.1. Overview; 11.2.2.2. Products & Services; 11.2.2.3. SWOT Analysis; 11.2.2.4. Recent Developments; 11.2.2.5. Strategies; 11.2.2.6. Financials (Based on Availability); 11.2.3. Aurobindo Pharmaceuticals; 11.2.3.1. Overview; 11.2.3.2. Products & Services; 11.2.3.3. SWOT Analysis; 11.2.3.4. Recent Developments; 11.2.3.5. Strategies; 11.2.3.6. Financials (Based on Availability); 11.2.4. Novartis AG; 11.2.4.1. Overview; 11.2.4.2. Products & Services; 11.2.4.3. SWOT Analysis; 11.2.4.4. Recent Developments; 11.2.4.5. Strategies; 11.2.4.6. Financials (Based on Availability); 11.2.5. Sanofi; 11.2.5.1. Overview; 11.2.5.2. Products & Services; 11.2.5.3. SWOT Analysis; 11.2.5.4. Recent Developments; 11.2.5.5. Strategies; 11.2.5.6. Financials (Based on Availability); 11.2.6. Bayer AG; 11.2.6.1. Overview; 11.2.6.2. Products & Services; 11.2.6.3. SWOT Analysis; 11.2.6.4. Recent Developments; 11.2.6.5. Strategies; 11.2.6.6. Financials (Based on Availability); 11.2.7. Par Pharmaceutical; 11.2.7.1. Overview; 11.2.7.2. Products & Services; 11.2.7.3. SWOT Analysis; 11.2.7.4. Recent Developments; 11.2.7.5. Strategies; 11.2.7.6. Financials (Based on Availability); 11.2.8. Sun Pharmaceutical Industries; 11.2.8.1. Overview; 11.2.8.2. Products & Services; 11.2.8.3. SWOT Analysis; 11.2.8.4. Recent Developments; 11.2.8.5. Strategies; 11.2.8.6. Financials (Based on Availability); 11.2.9. Teva Pharmaceutical Industries Ltd.; 11.2.9.1. Overview; 11.2.9.2. Products & Services; 11.2.9.3. SWOT Analysis; 11.2.9.4. Recent Developments; 11.2.9.5. Strategies; 11.2.9.6. Financials (Based on Availability); 12.